Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

27.22 +0.73 (+2.76%)
Official Closing Price Updated: 7:00 PM EST, Feb 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
3 Healthcare Stocks Paying the Highest Dividends of 2026 ↗
Which of the highest-yielding healthcare stocks are value traps or golden opportunities? 
Via The Motley Fool
News headline image
AstraZeneca’s Strategic Takeover of Modella AI Signals the Rise of Agentic Oncology
In a move that underscores the pharmaceutical industry’s aggressive pivot toward integrated artificial intelligence, AstraZeneca (NASDAQ: AZN) recently announced the full acquisition of Modella AI, a... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
Fiscal Brinkmanship: Data Blackout and the DHS Cliff Loom Over Markets After Narrow Funding Deal
In a week defined by high-stakes political theater and a brief but disruptive lapse in federal operations, Washington has managed to pull back from the edge of a total collapse—though only partially.... 
Via MarketMinute
Topics Economy Government Immigration
News headline image
Pfizer Maps Post-Covid Reset With Obesity Trials And Deep Cost Cuts ↗
Via Talk Markets
News headline image
The Great Pipeline Grab: Life Sciences Deal Volume Skyrockets 82% as Big Pharma Battles the Patent Cliff
The life sciences sector has entered 2026 in the midst of a historic transformation, as deal volume and value surged by a staggering 82% over the past year. This "Great Rebound," fueled by a... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
The Phoenix of Big Pharma: A 2026 Deep-Dive into AstraZeneca’s Global Dominance
As of February 6, 2026, AstraZeneca PLC (NASDAQ: AZN) stands as a case study in corporate resilience and strategic reinvention. Once a company teetering on the edge of a massive patent cliff a decade... 
Via Finterra
Topics Economy Government Intellectual Property
News headline image
Broad-Based Prosperity: S&P 500 Defies Headwinds with 10.1% Growth as Tech Reclaims Its Crown
The fourth-quarter earnings season of 2025 has reached a fever pitch, delivering a resounding message of resilience to Wall Street. As of February 6, 2026, the S&P 500 has reported an aggregate... 
Via MarketMinute
Topics Artificial Intelligence Earnings Economy
News headline image
Pfizer Pops on Q4 Results—But This May Be the Catalyst That Matters Most ↗
Via MarketBeat
News headline image
Trade War 2.0: 25% Tariffs on Chips, Cars, and Medicine Reshape the Global Supply Chain
The global economic landscape has been jolted in the opening weeks of 2026 as the United States government formalizes a series of aggressive 25% tariff proposals targeting the critical sectors of... 
Via MarketMinute
Topics Artificial Intelligence Earnings Economy
News headline image
The Great GLP-1 Divergence: Eli Lilly Surges Toward Trillion-Dollar Dominance as Novo Nordisk Falters on U.S. Price Cuts
In a dramatic week for the pharmaceutical sector, a stark rift has opened between the two undisputed titans of the weight-loss drug market. On February 4, 2026, Eli Lilly (NYSE:LLY) reported a... 
Via MarketMinute
Topics Earnings Economy
News headline image
Pfizer (PFE) Q4 2024 Earnings Call Transcript ↗
Pfizer (PFE) Q4 2024 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Pfizer (PFE) Q3 2024 Earnings Call Transcript ↗
Pfizer (PFE) Q3 2024 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Pfizer (PFE) Q2 2025 Earnings Call Transcript ↗
Pfizer (PFE) Q2 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings World Trade
News headline image
Trump Administration To Launch TrumpRx Platform For Discounted Drugs Later On Thursday: Reports ↗
The medications that will be offered via the platform include Novo Nordisk’s popular weight-loss drug Wegovy, Eli Lilly and Company's Zepbound, Amgen’s cholesterol drug Repatha, and Merck’s diabetes... 
Via Stocktwits
Topics Economy Government World Trade
News headline image
The $1 Trillion Apothecary: A Deep-Dive Research Report on Eli Lilly (LLY)
As of February 5, 2026, Eli Lilly and Company (NYSE: LLY) stands as a paradigm-shifting titan in the global healthcare landscape. Having recently crossed the historic $1 trillion market capitalization... 
Via Finterra
Topics Earnings Economy Intellectual Property
News headline image
Can Pfizer Crash the Lilly and Novo Nordisk Weight-Loss Party? ↗
Eli Lilly and Novo Nordisk may want to enjoy their duopoly while they can. 
Via The Motley Fool
These S&P500 stocks are the most active in today's session ↗
Via Chartmill
News headline image
Eli Lilly Soared by 39% in 2025, but Here's Another Healthcare Stock to Buy in 2026 ↗
Eli Lilly is riding the GLP-1 gravy train, while this competitor is struggling to get on board. 
Via The Motley Fool
AI Panic Hits Software, PayPal Faceplants, Walmart Joins the $1T Club ↗
Via Chartmill
Topics Artificial Intelligence
News headline image
PFE Q4 CY2025 Deep Dive: Obesity Pipeline and Cost Discipline Face Post-COVID Headwinds
Global pharmaceutical company Pfizer (NYSE:PFE) beat Wall Street’s revenue expectations in Q4 CY2025, but sales fell by 1.2% year on year to $17.56 billion. The company expects the full year’s revenue... 
Via StockStory
Topics Intellectual Property
News headline image
Will the Market Crash in 2026? Here's What History Says and What to Do About It ↗
Always be prepared. 
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
News headline image
3 Unprofitable Stocks with Questionable Fundamentals
Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure. 
Via StockStory
Topics Electric Vehicles
News headline image
Bristol-Myers Squibb Earnings: What To Look For From BMY
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be announcing earnings results this Thursday before the bell. Here’s what to expect. 
Via StockStory
News headline image
Why 2026 Could Be the Year Pfizer's Stock Finally Takes Off ↗
The company expects to launch more than 20 pivotal late-stage trials this year. 
Via The Motley Fool
Explore the S&P500 index on Tuesday and find out which stocks are the most active in today's session. ↗
Via Chartmill
Most active stocks in Tuesday's session ↗
Via Chartmill
News headline image
Pfizer (PFE) Q4 2025 Earnings Call Transcript ↗
Pfizer (PFE) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Why Pfizer Stock Dropped Today ↗
Is Pfizer stock a buy at under 9x earnings? Yes. It is. 
Via The Motley Fool
Topics Earnings
News headline image
Pfizer&#39;s Newly Acquired Drug Shows Weight Loss Of Just Around 13%, Stock Drops ↗
Pfizer reported strong mid-stage weight loss trial results for its monthly obesity drug and posted fourth-quarter earnings that beat analyst estimates, signaling progress in its obesity pipeline. 
Via Benzinga
News headline image
Pfizer Dives After Reaffirming Its Modest Outlook And Providing An Obesity Update ↗
Pfizer stock tumbled early Tuesday after the drugmaker reaffirmed its modest outlook for 2026 and provided an obesity update. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.